tetano
Editor, Senior Moderator
Cureus
. 2023 Jan 31;15(1):e34452.
doi: 10.7759/cureus.34452. eCollection 2023 Jan.
Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
Mohamed Elghazal[SUP] 1 [/SUP], Inas M Alhudiri[SUP] 2 [/SUP], Mohamed Said[SUP] 1 [/SUP], Eiman Elhouderi[SUP] 3 [/SUP], Adam Elzagheid[SUP] 2 [/SUP]
Affiliations
Abstract
Myocarditis and pericarditis are inflammatory conditions affecting the myocardium and pericardium, respectively. They are caused by infectious and non-infectious conditions, including autoimmune disorders, drugs, and toxins. Vaccine-induced myocarditis has been reported with viral vaccines, including influenza and smallpox. The BNT162b2 mRNA vaccine (Pfizer-BioNTech) has shown great efficacy against symptomatic, severe coronavirus disease 2019 (COVID-19), hospital admissions, and deaths. The US FDA issued an emergency use authorization for the Pfizer-BioNTech COVID-19 mRNA vaccine for the prevention of COVID-19 in individuals ≥ five years. However, concerns were raised after reports of new cases of myocarditis following mRNA COVID-19 vaccines, especially among adolescents and young adults. Most cases developed symptoms after receiving the second dose. Here, we present a case of a previously healthy 34-year-old male who developed sudden and severe chest pain a week after the second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine. Cardiac catheterization showed no angiographically obstructive coronary artery disease but it revealed intramyocardial bridging. This case report demonstrates that the mRNA COVID-19 vaccine can be associated with acute myopericarditis and the clinical presentation can mimic acute coronary syndrome. Despite that, acute myopericarditis associated with the mRNA COVID-19 vaccine is usually mild and can be managed conservatively. Incidental findings such as intramyocardial bridging should not exclude the diagnosis of myocarditis and should be carefully evaluated. COVID-19 infection has high mortality and morbidity even in young individuals, and all different COVID-19 vaccines were found effective in the prevention of severe COVID-19 infection and in decreasing COVID-19 mortality.
Keywords: bnt162b2; bnt162b2 mrna vaccine; coronavirus disease 2019; covid-19; covid-19 vaccine; intramyocardial bridging; mrna vaccination; myocarditis; pericarditis; pfizer-biontech.
. 2023 Jan 31;15(1):e34452.
doi: 10.7759/cureus.34452. eCollection 2023 Jan.
Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
Mohamed Elghazal[SUP] 1 [/SUP], Inas M Alhudiri[SUP] 2 [/SUP], Mohamed Said[SUP] 1 [/SUP], Eiman Elhouderi[SUP] 3 [/SUP], Adam Elzagheid[SUP] 2 [/SUP]
Affiliations
- PMID: 36874673
- PMCID: PMC9982053
- DOI: 10.7759/cureus.34452
Abstract
Myocarditis and pericarditis are inflammatory conditions affecting the myocardium and pericardium, respectively. They are caused by infectious and non-infectious conditions, including autoimmune disorders, drugs, and toxins. Vaccine-induced myocarditis has been reported with viral vaccines, including influenza and smallpox. The BNT162b2 mRNA vaccine (Pfizer-BioNTech) has shown great efficacy against symptomatic, severe coronavirus disease 2019 (COVID-19), hospital admissions, and deaths. The US FDA issued an emergency use authorization for the Pfizer-BioNTech COVID-19 mRNA vaccine for the prevention of COVID-19 in individuals ≥ five years. However, concerns were raised after reports of new cases of myocarditis following mRNA COVID-19 vaccines, especially among adolescents and young adults. Most cases developed symptoms after receiving the second dose. Here, we present a case of a previously healthy 34-year-old male who developed sudden and severe chest pain a week after the second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine. Cardiac catheterization showed no angiographically obstructive coronary artery disease but it revealed intramyocardial bridging. This case report demonstrates that the mRNA COVID-19 vaccine can be associated with acute myopericarditis and the clinical presentation can mimic acute coronary syndrome. Despite that, acute myopericarditis associated with the mRNA COVID-19 vaccine is usually mild and can be managed conservatively. Incidental findings such as intramyocardial bridging should not exclude the diagnosis of myocarditis and should be carefully evaluated. COVID-19 infection has high mortality and morbidity even in young individuals, and all different COVID-19 vaccines were found effective in the prevention of severe COVID-19 infection and in decreasing COVID-19 mortality.
Keywords: bnt162b2; bnt162b2 mrna vaccine; coronavirus disease 2019; covid-19; covid-19 vaccine; intramyocardial bridging; mrna vaccination; myocarditis; pericarditis; pfizer-biontech.